MUMBAI (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd said on Friday it has received final approval from the U.S. Food and Drug Administration (FDA) to make a cheaper version of Roche Holding AG's antiviral Valcyte, sending its stock to a record high.
The move comes after Ranbaxy Laboratories Ltd said on Thursday that FDA had stripped the company of its tentative approval to launch the first copy of the drug due to quality control issues at its manufacturing plants.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch20
01:45 Japanese shares fall 1% as yen strengthens, Samsung presser announcements ahead18
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High10